Protara Therapeutics Future Growth
Future criteria checks 0/6
Protara Therapeutics's earnings are forecast to decline at 5.1% per annum while its annual revenue is expected to grow at 71.1% per year. EPS is expected to grow by 13% per annum.
Key information
-5.1%
Earnings growth rate
13.0%
EPS growth rate
| Biotechs earnings growth | 35.6% |
| Revenue growth rate | 71.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | -67 | -56 | N/A | 3 |
| 12/31/2025 | N/A | -56 | -46 | N/A | 4 |
| 12/31/2024 | N/A | -43 | -36 | N/A | 4 |
| 6/30/2024 | N/A | -41 | -33 | -33 | N/A |
| 3/31/2024 | N/A | -42 | -35 | -35 | N/A |
| 12/31/2023 | N/A | -40 | -38 | -38 | N/A |
| 9/30/2023 | N/A | -69 | -34 | -34 | N/A |
| 6/30/2023 | N/A | -67 | -33 | -33 | N/A |
| 3/31/2023 | N/A | -64 | -28 | -28 | N/A |
| 12/31/2022 | N/A | -66 | -27 | -26 | N/A |
| 9/30/2022 | N/A | -37 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -40 | -29 | -29 | N/A |
| 3/31/2022 | N/A | -45 | -34 | -34 | N/A |
| 12/31/2021 | N/A | -47 | -35 | -35 | N/A |
| 9/30/2021 | N/A | -46 | -35 | -34 | N/A |
| 6/30/2021 | N/A | -43 | -33 | -32 | N/A |
| 3/31/2021 | N/A | -37 | -29 | -28 | N/A |
| 12/31/2020 | N/A | -34 | -24 | -23 | N/A |
| 9/30/2020 | N/A | -28 | -18 | -18 | N/A |
| 6/30/2020 | N/A | -22 | -16 | -15 | N/A |
| 3/31/2020 | N/A | -16 | -11 | -11 | N/A |
| 12/31/2019 | N/A | -8 | -5 | -5 | N/A |
| 9/30/2019 | N/A | -7 | -5 | -5 | N/A |
| 12/31/2018 | N/A | -4 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1KPA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1KPA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1KPA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1KPA is forecast to have no revenue next year.
High Growth Revenue: 1KPA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1KPA's Return on Equity is forecast to be high in 3 years time